Currently out of the existing stock ratings of Evan Seigerman, 355 are a BUY (68.4%), 141 are a HOLD (27.17%), 23 are a SELL (4.43%).

Evan Seigerman

Work Performance Price Targets & Ratings Chart

Analyst Evan Seigerman, currently employed at BMO, carries an average stock price target met ratio of 66.92% that have a potential upside of 29.33% achieved within 237 days.

Evan Seigerman’s has documented 1,027 price targets and ratings displayed on 40 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 25-Sep-2026.

Wall Street Analyst Evan Seigerman

Analyst best performing recommendations are on TERN (TERNS PHARMACEUTICALS).
The best stock recommendation documented was for NVO (NOVO NORDISK A/S) at 2/5/2026. The price target of $45 was fulfilled within 1 day with a profit of $3.72 (9.01%) receiving and performance score of 90.12.

Average potential price target upside

of $137.03 (22.05%) on LLY (ELI LILLY AND COMPANY).
of $128.3 (21.38%) on REGN (REGENERON PHARMACEUTICALS).
of $60.08 (18.75%) on VRTX (VERTEX PHARMACEUTICALS).

ACRX AcelRx Pharmaceuticals AIMT Aimmune Therapeutics AMGN Amgen BIIB Biogen BMY Bristol-Myers Squibb Company GILD Gilead Sciences GRTX Galera Therapeutics INCY yte LLY Eli Lilly and Company MRTX Mirati Ther NBIX Neurocrine Biosciences PFE Pfizer REGN Regeneron Pharmaceuticals STSA Satsuma Pharmaceuticals VRTX Vertex Pharmaceuticals NUVB Nuvation Bio REPL Replimune Group CADL Candel Therapeutics MGNX MacroGenics MRK Merck mpany GLPG Galapagos NV ADR IKNA Ikena Oncology MORF Morphic GPCR Structure Therapeutics American Depositary Shares IRON Disc Medicine ALDR Alder BioPharmaceuticals NVO Novo Nordisk A/S ABBV AbbVie ACAD ACADIA Pharmaceuticals AI C3 Ai BNTX BioNTech SE PTGX Protagonist Therapeutics SDGR Schrodinger SRRK Scholar Rock Holding Corp ST Sensata Technologies Holding NV TERN Terns Pharmaceuticals NGNE Neurogene ARVN Arvinas MRUS Merus BV TSHA Taysha Gene Therapies

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Ed Arce (WESTPARK)

Buy Since 25-Sep-2023

2 years 10 months 5 days ago
(07-Dec-2023)

0/6 (0%)

$4.4 (733.33%)

Please subscribe to see extended stock data

Brandon Folkes (HC WAINWRIGHT)

Buy Since 05-Nov-2018

$2.87 (253.98%)

4 years 10 months 11 days ago
(01-Dec-2021)

2/2 (100%)

$-8.43 (-67.82%)

670

Please subscribe to see extended stock data

Michael Higgins (LADENBURG)

Buy Since 16-Aug-2018

$2.87 (253.98%)

5 years 6 months 26 days ago
(16-Mar-2021)

3/3 (100%)

$-33.2 (-89.25%)

1106

Please subscribe to see extended stock data

Evan Seigerman (BMO)

Sell Since 13-Aug-2020

$16.6

$15.47 (1369.03%)

$16.8

5 years 11 months 6 days ago
(06-Nov-2020)

4/4 (100%)

$-12.4 (-42.76%)

335

Please subscribe to see extended stock data

Randall Stanicky

Buy Since 16-Aug-2016

$120

$118.87 (10519.47%)

$140

7 years 5 months 3 days ago
(09-May-2019)

0/4 (0%)

$56.4 (88.68%)

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Evan Seigerman most bullish on?

Potential upside of $120.73 has been obtained for LLY (ELI LILLY AND COMPANY)

Which stock is Evan Seigerman most reserved on?

Potential downside of -$31.73 has been obtained for PTGX (PROTAGONIST THERAPEUTICS)

What Year was the first public recommendation made by Evan Seigerman?

On 2019